{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:00:02Z","timestamp":1781139602920,"version":"3.54.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No. 2022YFA1105604"],"award-info":[{"award-number":["No. 2022YFA1105604"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05020-6","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:15:34Z","timestamp":1777130134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset"],"prefix":"10.1186","volume":"17","author":[{"given":"Meng-Qi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Fei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Di","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"5020_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","volume":"403","author":"Global age-sex-specific mortality","year":"2024","unstructured":"Global age-sex-specific mortality. life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:1989\u20132056.","journal-title":"Lancet"},{"key":"5020_CR2","unstructured":"Coronavirus disease (COVID-19) situation reports [https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports]"},{"key":"5020_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/d41586-023-01437-8","volume":"617","author":"E Callaway","year":"2023","unstructured":"Callaway E. COVID\u2019s future: mini-waves rather than seasonal surges. Nature. 2023;617:229\u201330.","journal-title":"Nature"},{"key":"5020_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417\u20138.","journal-title":"Lancet"},{"key":"5020_CR5","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1053\/j.gastro.2020.02.055","volume":"158","author":"F Xiao","year":"2020","unstructured":"Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158:1831-1833.e1833.","journal-title":"Gastroenterology"},{"key":"5020_CR6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","volume":"181","author":"CGK Ziegler","year":"2020","unstructured":"Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016-1035.e1019.","journal-title":"Cell"},{"key":"5020_CR7","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M\u00f8ller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036-1045.e1039.","journal-title":"Cell"},{"key":"5020_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"key":"5020_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"5020_CR10","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41591-024-03173-6","volume":"30","author":"Z Al-Aly","year":"2024","unstructured":"Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, et al. Long COVID science, research and policy. Nat Med. 2024;30:2148\u201364.","journal-title":"Nat Med"},{"key":"5020_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(24)01136-X","volume":"404","author":"T Greenhalgh","year":"2024","unstructured":"Greenhalgh T, Sivan M, Perlowski A, Nikolich J. Long COVID: a clinical update. Lancet. 2024;404:707\u201324.","journal-title":"Lancet"},{"key":"5020_CR12","doi-asserted-by":"crossref","unstructured":"Ai J, Guo J, Lin K, Cai J, Zhang H, Zhu F, Sun G, Xue Q, Zhu K, Yang Y, et al. Integrated multi-omics characterization across clinically relevant subgroups of long COVID. Natl Sci Rev. 2024.","DOI":"10.1093\/nsr\/nwae410"},{"key":"5020_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(22)00126-6","volume":"10","author":"L Huang","year":"2022","unstructured":"Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863\u201376.","journal-title":"Lancet Respir Med"},{"key":"5020_CR14","first-page":"101218","volume":"52","author":"S Qin","year":"2024","unstructured":"Qin S, Zhang Y, Li Y, Huang L, Yang T, Si J, et al. Long COVID facts and findings: a large-scale online survey in 74,075 Chinese participants. Lancet Reg Health West Pac. 2024;52:101218.","journal-title":"Lancet Reg Health West Pac"},{"key":"5020_CR15","first-page":"2402961","volume":"2020","author":"X Wang","year":"2020","unstructured":"Wang X, Fang X, Cai Z, Wu X, Gao X, Min J, et al. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis. Research (Wash D C). 2020;2020:2402961.","journal-title":"Research (Wash D C)"},{"key":"5020_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.46234\/ccdcw2023.075","volume":"5","author":"C Cai","year":"2023","unstructured":"Cai C, Li Y, Hu T, Liang R, Wang K, Guo C, et al. The associated factors of SARS-CoV-2 reinfection by omicron variant\u2014Guangdong Province, China, December 2022 to January 2023. China CDC Wkly. 2023;5:391\u20136.","journal-title":"China CDC Wkly"},{"key":"5020_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan Y, Zhou H, Liu X, Iketani S, Lin M, Zhang X, et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;622:376\u201382.","journal-title":"Nature"},{"key":"5020_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov PV, Ghafari M, Beer M, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21:361\u201379.","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"5020_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S1473-3099(24)00158-0","volume":"24","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Mestrovic T, Gray A, Hayoon AG, Swetschinski LR, Aguilar GR, et al. Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Infect Dis. 2024;24(8):868\u201395.","journal-title":"Lancet Infect Dis"},{"key":"5020_CR20","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1016\/S2468-2667(20)30264-4","volume":"5","author":"L Shang","year":"2020","unstructured":"Shang L, Xu J, Cao B. Viral pneumonia in China: from surveillance to response. Lancet Public Health. 2020;5:e633\u20134.","journal-title":"Lancet Public Health"},{"key":"5020_CR21","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2024.7395","volume":"331","author":"Y Xie","year":"2024","unstructured":"Xie Y, Choi T, Al-Aly Z. Mortality in patients hospitalized for COVID-19 vs influenza in fall-winter 2023\u20132024. JAMA. 2024;331:1963\u20135.","journal-title":"JAMA"},{"key":"5020_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-052422-020316","volume":"75","author":"HS Andrews","year":"2024","unstructured":"Andrews HS, Herman JD, Gandhi RT. Treatments for COVID-19. Annu Rev Med. 2024;75:145\u201357.","journal-title":"Annu Rev Med"},{"key":"5020_CR23","doi-asserted-by":"publisher","first-page":"e0011923","DOI":"10.1128\/cmr.00119-23","volume":"37","author":"D Focosi","year":"2024","unstructured":"Focosi D, Franchini M, Maggi F, Shoham S. COVID-19 therapeutics. Clin Microbiol Rev. 2024;37:e0011923.","journal-title":"Clin Microbiol Rev"},{"key":"5020_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22:449\u201375.","journal-title":"Nat Rev Drug Discov"},{"key":"5020_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7:272.","journal-title":"Signal Transduct Target Ther"},{"key":"5020_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12016-025-09030-9","volume":"68","author":"L Li","year":"2025","unstructured":"Li L, He Y, Zhao J, Yin H, Feng X, Fan X, et al. Mesenchymal stromal cell-based therapy: a promising approach for autoimmune diseases. Clin Rev Allergy Immunol. 2025;68:21.","journal-title":"Clin Rev Allergy Immunol"},{"key":"5020_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726\u201336.","journal-title":"Nat Rev Immunol"},{"key":"5020_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41392-021-00754-6","volume":"6","author":"L Shi","year":"2021","unstructured":"Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, et al. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct Target Ther. 2021;6:339.","journal-title":"Signal Transduct Target Ther"},{"key":"5020_CR29","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1097\/JS9.0000000000001786","volume":"110","author":"C Tang","year":"2024","unstructured":"Tang C, Dziedzic A, Khatib MN, Alhumaid S, Thangavelu L, Parameswari RP, et al. Stem cell therapy for COVID-19 treatment: an umbrella review. Int J Surg. 2024;110:6402\u201317.","journal-title":"Int J Surg"},{"key":"5020_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.202201-0157OC","volume":"207","author":"ME Bowdish","year":"2023","unstructured":"Bowdish ME, Barkauskas CE, Overbey JR, Gottlieb RL, Osman K, Duggal A, et al. A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19. Am J Respir Crit Care Med. 2023;207:261\u201370.","journal-title":"Am J Respir Crit Care Med"},{"key":"5020_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1164\/rccm.202302-0297OC","volume":"208","author":"EA Gorman","year":"2023","unstructured":"Gorman EA, Rynne J, Gardiner HJ, Rostron AJ, Bannard-Smith J, Bentley AM, et al. Repair of acute respiratory distress syndrome in COVID-19 by Stromal cells (REALIST-COVID Trial): a multicenter, randomized, controlled clinical trial. Am J Respir Crit Care Med. 2023;208:256\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"5020_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","volume":"5","author":"F Meng","year":"2020","unstructured":"Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5:172.","journal-title":"Signal Transduct Target Ther"},{"key":"5020_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13054-022-03930-4","volume":"26","author":"A Monsel","year":"2022","unstructured":"Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care. 2022;26:48.","journal-title":"Crit Care"},{"key":"5020_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","volume":"6","author":"L Shi","year":"2021","unstructured":"Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021;6:58.","journal-title":"Signal Transduct Target Ther"},{"key":"5020_CR35","first-page":"1444","volume":"164","author":"AL Lightner","year":"2023","unstructured":"Lightner AL, Sengupta V, Qian S, Ransom JT, Suzuki S, Park DJ, et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: a randomized. Placebo-Controlled Dosing Clinical Trial Chest. 2023;164:1444\u201353.","journal-title":"Placebo-Controlled Dosing Clinical Trial Chest"},{"key":"5020_CR36","first-page":"1153","volume":"6","author":"J Chen","year":"2020","unstructured":"Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering (Beijing). 2020;6:1153\u201361.","journal-title":"Engineering (Beijing)"},{"key":"5020_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13287-022-02960-7","volume":"13","author":"Y Qu","year":"2022","unstructured":"Qu Y, Yang X, Zhang X, Liu S, Liu X, Liu X, et al. Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study. Stem Cell Res Ther. 2022;13:277.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR38","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/thorax-2024-222026","volume":"79","author":"TDY Reijnders","year":"2024","unstructured":"Reijnders TDY, Laterre PF, Fran\u00e7ois B, S\u00e1nchez Garc\u00eda M, van Engelen TSR, Sie D, et al. Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia. Thorax. 2024;79:1086\u201390.","journal-title":"Thorax"},{"key":"5020_CR39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/14712598.2022.2016695","volume":"22","author":"LL Bagno","year":"2022","unstructured":"Bagno LL, Salerno AG, Balkan W, Hare JM. Mechanism of action of mesenchymal stem cells (MSCs): impact of delivery method. Expert Opin Biol Ther. 2022;22:449\u201363.","journal-title":"Expert Opin Biol Ther"},{"key":"5020_CR40","doi-asserted-by":"crossref","unstructured":"Carp DM, Liang Y. Universal or personalized mesenchymal stem cell therapies: impact of age, sex, and biological source. Cells 2022;11.","DOI":"10.3390\/cells11132077"},{"key":"5020_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13287-024-03689-1","volume":"15","author":"M Hao","year":"2024","unstructured":"Hao M, Jiang H, Zhao Y, Li C, Jiang J. Identification of potential biomarkers for aging diagnosis of mesenchymal stem cells derived from the aged donors. Stem Cell Res Ther. 2024;15:87.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3892\/ijmm.2015.2413","volume":"37","author":"JS Heo","year":"2016","unstructured":"Heo JS, Choi Y, Kim HS, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37:115\u201325.","journal-title":"Int J Mol Med"},{"key":"5020_CR43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s13287-024-03977-w","volume":"15","author":"S Regmi","year":"2024","unstructured":"Regmi S, Ganguly A, Pathak S, Primavera R, Chetty S, Wang J, et al. Evaluating the therapeutic potential of different sources of mesenchymal stem cells in acute respiratory distress syndrome. Stem Cell Res Ther. 2024;15:385.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR44","doi-asserted-by":"publisher","first-page":"e28702","DOI":"10.1002\/jmv.28702","volume":"95","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Shao S, Liu X, Tong Z. Effect and safety of mesenchymal stem cells for patients with COVID-19: Systematic review and meta-analysis with trial sequential analysis. J Med Virol. 2023;95:e28702.","journal-title":"J Med Virol"},{"key":"5020_CR45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s12967-024-05358-6","volume":"22","author":"W Lu","year":"2024","unstructured":"Lu W, Yan L, Tang X, Wang X, Du J, Zou Z, et al. Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. J Transl Med. 2024;22:550.","journal-title":"J Transl Med"},{"key":"5020_CR46","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1002\/iid3.1000","volume":"11","author":"C Yan","year":"2023","unstructured":"Yan C, Hu M, Dai R. Safety and efficacy of mesenchymal stem cells in COVID-19 patients: a systematic review and meta-analysis. Immun Inflamm Dis. 2023;11:e1000.","journal-title":"Immun Inflamm Dis"},{"key":"5020_CR47","doi-asserted-by":"publisher","first-page":"1200180","DOI":"10.3389\/fimmu.2023.1200180","volume":"14","author":"PS Couto","year":"2023","unstructured":"Couto PS, Al-Arawe N, Filgueiras IS, Fonseca DLM, Hinterseher I, Catar RA, et al. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety\/efficacy outcomes, cell product manufacturing and clinical delivery. Front Immunol. 2023;14:1200180.","journal-title":"Front Immunol"},{"key":"5020_CR48","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"5020_CR49","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"5020_CR50","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"5020_CR51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"5020_CR52","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991\u20136.","journal-title":"J Clin Epidemiol"},{"key":"5020_CR53","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"5020_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2288-11-41","volume":"11","author":"J Bowden","year":"2011","unstructured":"Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.","journal-title":"BMC Med Res Methodol"},{"key":"5020_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"5020_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193\u2013206.","journal-title":"Psychol Methods"},{"key":"5020_CR57","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","volume":"11","author":"L Shu","year":"2020","unstructured":"Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11:361.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR58","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1089\/scd.2021.0015","volume":"30","author":"G Feng","year":"2021","unstructured":"Feng G, Shi L, Huang T, Ji N, Zheng Y, Lin H, et al. Human umbilical cord mesenchymal stromal cell treatment of severe COVID-19 patients: a 3-month follow-up study following hospital discharge. Stem Cells Dev. 2021;30:773\u201381.","journal-title":"Stem Cells Dev"},{"key":"5020_CR59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13287-022-02972-3","volume":"13","author":"L Shi","year":"2022","unstructured":"Shi L, Zheng Y, Cheng Z, Ji N, Niu C, Wang Y, et al. One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment. Stem Cell Res Ther. 2022;13:321.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR60","doi-asserted-by":"publisher","first-page":"103789","DOI":"10.1016\/j.ebiom.2021.103789","volume":"75","author":"L Shi","year":"2022","unstructured":"Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022;75:103789.","journal-title":"EBioMedicine"},{"key":"5020_CR61","doi-asserted-by":"publisher","first-page":"104600","DOI":"10.1016\/j.ebiom.2023.104600","volume":"92","author":"TT Li","year":"2023","unstructured":"Li TT, Zhang B, Fang H, Shi M, Yao WQ, Li Y, et al. Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2023;92:104600.","journal-title":"EBioMedicine"},{"key":"5020_CR62","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13287-022-02920-1","volume":"13","author":"N Kaffash Farkhad","year":"2022","unstructured":"Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, et al. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Res Ther. 2022;13:283.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR63","first-page":"687","volume":"21","author":"N Kaffash Farkhad","year":"2022","unstructured":"Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, et al. Specific clinical and immunological changes following mesenchymal stem cell transplantation in COVID-19-induced Acute respiratory distress syndrome patients: a phase-I clinical trial. Iran J Allergy Asthma Immunol. 2022;21:687\u2013703.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"5020_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13287-024-03729-w","volume":"15","author":"A Sitbon","year":"2024","unstructured":"Sitbon A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Diehl JL, et al. Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life. Stem Cell Res Ther. 2024;15:109.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR65","doi-asserted-by":"publisher","first-page":"1001979","DOI":"10.3389\/fmed.2022.1001979","volume":"9","author":"CH Chen","year":"2022","unstructured":"Chen CH, Chang KC, Lin YN, Ho MW, Cheng MY, Shih WH, et al. Mesenchymal stem cell therapy on top of triple therapy with remdesivir, dexamethasone, and tocilizumab improves PaO(2)\/FiO(2) in severe COVID-19 pneumonia. Front Med (Lausanne). 2022;9:1001979.","journal-title":"Front Med (Lausanne)"},{"key":"5020_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13287-023-03402-8","volume":"14","author":"M Zarrabi","year":"2023","unstructured":"Zarrabi M, Shahrbaf MA, Nouri M, Shekari F, Hosseini SE, Hashemian SR, et al. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial. Stem Cell Res Ther. 2023;14:169.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR67","doi-asserted-by":"publisher","first-page":"963689721102494","DOI":"10.1177\/09636897211024942","volume":"30","author":"G Adas","year":"2021","unstructured":"Adas G, Cukurova Z, Yasar KK, Yilmaz R, Isiksacan N, Kasapoglu P, et al. The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial. Cell Transplant. 2021;30:9636897211024942.","journal-title":"Cell Transplant"},{"key":"5020_CR68","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216\u201328.","journal-title":"Aging Dis"},{"key":"5020_CR69","doi-asserted-by":"publisher","first-page":"e2604","DOI":"10.6061\/clinics\/2021\/e2604","volume":"76","author":"F Wei","year":"2021","unstructured":"Wei F, Kong D, Li T, Li A, Tan Y, Fang J, et al. Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19. Clinics (Sao Paulo). 2021;76:e2604.","journal-title":"Clinics (Sao Paulo)"},{"key":"5020_CR70","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/0885066621997365","volume":"36","author":"H H\u00e4berle","year":"2021","unstructured":"H\u00e4berle H, Magunia H, Lang P, Gloeckner H, K\u00f6rner A, Koeppen M, et al. Mesenchymal stem cell therapy for severe COVID-19 ARDS. J Intensive Care Med. 2021;36:681\u20138.","journal-title":"J Intensive Care Med"},{"key":"5020_CR71","doi-asserted-by":"crossref","unstructured":"Bukreieva T, Svitina H, Nikulina V, Vega A, Chybisov O, Shablii I, Ustymenko A, Nemtinov P, Lobyntseva G, Skrypkina I, Shablii V. Treatment of acute respiratory distress syndrome caused by COVID-19 with human umbilical cord mesenchymal stem cells. Int J Mol Sci 2023;24.","DOI":"10.3390\/ijms24054435"},{"key":"5020_CR72","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/sctm.21-0046","volume":"10","author":"IH Dilogo","year":"2021","unstructured":"Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. Stem Cells Transl Med. 2021;10:1279\u201387.","journal-title":"Stem Cells Transl Med"},{"key":"5020_CR73","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sctm.20-0472","volume":"10","author":"G Lanzoni","year":"2021","unstructured":"Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10:660\u201373.","journal-title":"Stem Cells Transl Med"},{"key":"5020_CR74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13287-022-02796-1","volume":"13","author":"CLK Rebelatto","year":"2022","unstructured":"Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, et al. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther. 2022;13:122.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR75","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.1038\/s41598-023-39268-2","volume":"13","author":"B Soetjahjo","year":"2023","unstructured":"Soetjahjo B, Malueka RG, Nurudhin A, Purwoko S, Wisaksana R, Adhiputri A, et al. Effectiveness and safety of normoxic allogenic umbilical cord mesenchymal stem cells administered as adjunctive treatment in patients with severe COVID-19. Sci Rep. 2023;13:12520.","journal-title":"Sci Rep"},{"key":"5020_CR76","doi-asserted-by":"publisher","first-page":"932360","DOI":"10.3389\/fimmu.2022.932360","volume":"13","author":"C Gr\u00e9goire","year":"2022","unstructured":"Gr\u00e9goire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, et al. Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I\/II clinical trial. Front Immunol. 2022;13:932360.","journal-title":"Front Immunol"},{"key":"5020_CR77","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13287-022-02953-6","volume":"13","author":"HR Aghayan","year":"2022","unstructured":"Aghayan HR, Salimian F, Abedini A, Fattah Ghazi S, Yunesian M, Alavi-Moghadam S, et al. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Stem Cell Res Ther. 2022;13:365.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR78","doi-asserted-by":"publisher","first-page":"871828","DOI":"10.3389\/fimmu.2022.871828","volume":"13","author":"MC Chen","year":"2022","unstructured":"Chen MC, Lai KS, Chien KL, Teng ST, Lin YR, Chao W, et al. pcMSC modulates immune dysregulation in patients with COVID-19-induced refractory acute lung injury. Front Immunol. 2022;13:871828.","journal-title":"Front Immunol"},{"key":"5020_CR79","doi-asserted-by":"publisher","first-page":"1224865","DOI":"10.3389\/fmed.2023.1224865","volume":"10","author":"C Pochon","year":"2023","unstructured":"Pochon C, Laroye C, Kimmoun A, Reppel L, Dhuyser A, Rousseau H, et al. Efficacy of Wharton jelly mesenchymal stromal cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial. Front Med (Lausanne). 2023;10:1224865.","journal-title":"Front Med (Lausanne)"},{"key":"5020_CR80","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1002\/ctm2.297","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial. Clin Transl Med. 2021;11:e297.","journal-title":"Clin Transl Med"},{"key":"5020_CR81","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4274\/tjh.galenos.2022.2022.0103","volume":"39","author":"H Canbaz","year":"2022","unstructured":"Canbaz H, \u0130diz UO, Dal Cankar H, Ka\u00e7\u0131ro\u011flu F, Ta\u015f S, \u00c7ubuk\u00e7u HC, et al. Effectiveness of mesenchymal stem cell therapy for COVID-19 patients in the intensive care unit: a case-control study. Turk J Haematol. 2022;39:222\u20139.","journal-title":"Turk J Haematol"},{"key":"5020_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s41231-021-00101-5","volume":"6","author":"Y Ventura-Carmenate","year":"2021","unstructured":"Ventura-Carmenate Y, Alkaabi FM, Castillo-Aleman YM, Villegas-Valverde CA, Ahmed YM, Sanna P, et al. Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020. Transl Med Commun. 2021;6:25.","journal-title":"Transl Med Commun"},{"key":"5020_CR83","doi-asserted-by":"publisher","first-page":"116","DOI":"10.69854\/jcq.2024.0016","volume":"1","author":"N Horita","year":"2024","unstructured":"Horita N, Yamamoto S, Mizuki Y, Kawagoe T, Mihara T, Yamashiro T. Minimal clinically important difference (MCID) of effect sizes other than mean difference. J Clin Question. 2024;1:116\u201327.","journal-title":"J Clin Question"},{"key":"5020_CR84","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1473-3099(24)00171-3","volume":"24","author":"W Zuo","year":"2024","unstructured":"Zuo W, He D, Liang C, Du S, Hua Z, Nie Q, et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis. 2024;24:845\u201355.","journal-title":"Lancet Infect Dis"},{"key":"5020_CR85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2213-2600(23)00387-9","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H, Huang C, Gu X, Wang Y, Li X, Liu M, et al. 3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study. Lancet Respir Med. 2024;12:55\u201366.","journal-title":"Lancet Respir Med"},{"key":"5020_CR86","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","volume":"612","author":"SR Stein","year":"2022","unstructured":"Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758\u201363.","journal-title":"Nature"},{"key":"5020_CR87","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(23)00239-4","volume":"11","author":"M Parotto","year":"2023","unstructured":"Parotto M, Gy\u00f6ngy\u00f6si M, Howe K, Myatra SN, Ranzani O, Shankar-Hari M, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med. 2023;11:739\u201354.","journal-title":"Lancet Respir Med"},{"key":"5020_CR88","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13287-025-04148-1","volume":"16","author":"MQ Yuan","year":"2025","unstructured":"Yuan MQ, Song L, Wang ZR, Zhang ZY, Shi M, He J, et al. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther. 2025;16:94.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR89","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","volume":"14","author":"Y Shi","year":"2018","unstructured":"Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14:493\u2013507.","journal-title":"Nat Rev Nephrol"},{"key":"5020_CR90","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.stem.2022.10.001","volume":"29","author":"Y Wang","year":"2022","unstructured":"Wang Y, Fang J, Liu B, Shao C, Shi Y. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell. 2022;29:1515\u201330.","journal-title":"Cell Stem Cell"},{"key":"5020_CR91","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.cell.2024.07.054","volume":"187","author":"MJ Peluso","year":"2024","unstructured":"Peluso MJ, Deeks SG. Mechanisms of long COVID and the path toward therapeutics. Cell. 2024;187:5500\u201329.","journal-title":"Cell"},{"key":"5020_CR92","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13287-023-03522-1","volume":"14","author":"R Vij","year":"2023","unstructured":"Vij R, Kim H, Park H, Cheng T, Lotfi D, Chang D. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. Stem Cell Res Ther. 2023;14:287.","journal-title":"Stem Cell Res Ther"},{"key":"5020_CR93","doi-asserted-by":"publisher","first-page":"e2410579121","DOI":"10.1073\/pnas.2410579121","volume":"121","author":"F Zhu","year":"2024","unstructured":"Zhu F, Ji L, Dai K, Deng S, Wang J, Liu C. In situ licensing of mesenchymal stem cell immunomodulatory function via BMP-2 induced developmental process. Proc Natl Acad Sci USA. 2024;121:e2410579121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5020_CR94","doi-asserted-by":"publisher","first-page":"2002944","DOI":"10.1002\/advs.202002944","volume":"8","author":"A Andrzejewska","year":"2021","unstructured":"Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal stem cells for neurological disorders. Adv Sci (Weinh). 2021;8:2002944.","journal-title":"Adv Sci (Weinh)"},{"key":"5020_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2020.04.035","volume":"110","author":"IA Deus","year":"2020","unstructured":"Deus IA, Mano JF, Cust\u00f3dio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020;110:1\u201314.","journal-title":"Acta Biomater"},{"key":"5020_CR96","doi-asserted-by":"publisher","first-page":"20742","DOI":"10.1021\/acsami.3c01741","volume":"15","author":"H Yang","year":"2023","unstructured":"Yang H, Wu Q, Li J, Chen Q, Su L, He X, et al. In Vivo Fate of CXCR2-overexpressing mesenchymal stromal\/stem cells in pulmonary diseases monitored by near-infrared region 2 imaging. ACS Appl Mater Interfaces. 2023;15:20742\u201352.","journal-title":"ACS Appl Mater Interfaces"},{"key":"5020_CR97","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jconrel.2022.03.025","volume":"345","author":"R Zhao","year":"2022","unstructured":"Zhao R, Wang L, Wang T, Xian P, Wang H, Long Q. Inhalation of MSC-EVs is a noninvasive strategy for ameliorating acute lung injury. J Control Release. 2022;345:214\u201330.","journal-title":"J Control Release"},{"key":"5020_CR98","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/sctm.17-0129","volume":"6","author":"RM Samsonraj","year":"2017","unstructured":"Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 2017;6:2173\u201385.","journal-title":"Stem Cells Transl Med"},{"key":"5020_CR99","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41392-025-02318-4","volume":"10","author":"L Shi","year":"2025","unstructured":"Shi L, Zhang Z, Mei S, Wang Z, Xu Z, Yao W, et al. Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia\/Ib results and immune modulation insights. Signal Transduct Target Ther. 2025;10:238.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05020-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:03:52Z","timestamp":1781136232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05020-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5020"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05020-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}